We offer clinical trials for a wide range of conditions including Anal Cancer, Biliary Cancer (Bile Duct & Gallbladder), Colon Cancer, Esophageal Cancer, Gastric Cancer, Neuroendocrine Tumors, Pancreatic Cancer, Rectal Cancer, as well as Phase I Solid Tumor studies. Many of these trials are led by Principal Investigators in the GI Oncology Program including Emily Bergsland, M.D., Andrew H. Ko, M.D. and Alan P. Venook, M.D.
The physician-scientists and basic researchers in the Surgical Oncology Research Lab under the leadership of Dr. Robert Warren, Chief of the Surgical Oncology Program are conducting research aimed at identifying lesions that lead to the development and spread of cancer.
Researchers in the lab are focused on identifying lesions associated with the tumorigenesis and metastasis. The Surgical Oncology Tumor Bank has been invaluable in advancing this research possible. For example, the lab was able to help validate the role of microRNAs in a mouse model of pancreatic neuroendocrine tumors using human neuroendocrine tumor specimens. The lab is also investigating the role of Sall2 in conferring resistance to cancer therapies, how TNFR1 signaling contributes to the inflammatory response and cell apoptosis, and the role of colon cancer stem cells in perpetuating tumor growth.